Prof. Dr. med. Dr. h.c. Christoph Lange

Stand: 01.01.2026

Personal Data

• Name: Christoph Lange
• Place/date of birth: Essen/ 22.06.1962
• Academic titles: Univ. Prof. Dr. med. Dr. h. c. Dipl- Biol. FERS, FESCMID, FIDSA, FRCP

Affiliations

• Main employment: Medical Director, Research Center Borstel, Borstel, Germany
• Address: Parkallee 35, D-23845 Borstel
• Phone/Fax/ Email: +49 4537 188 3010/ +49 4537 188 6030/ Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein.

Education/Training

• 2022: Board certification „Internal Medicine and Infectious Diseases“
• 2009: Board certification „Sleep Medicine“
• 2008: Board certification „Critical Care Medicine“
• 2008: Board certification „Allergology“
• 2006: Board certification „Infectious Diseases“
• 2003: Board certification „Pulmonology“
• 2001-2009: Subspeciality training, Medical Clinic, Research Center Borstel
• 2001: Board certification „Internal Medicine“
• 1999-2001: Fellowship in Infectious Diseases (CWRU, Cleveland, Ohio, USA)
• 1994-1999: Training in Internal Medicine (Cape Town, RSA; Preetz and Rendsburg)
• 1988-1994: Medicine, Board Licensing Examination (University of Witten-Herdecke)
• 1983-1988: Biology Diploma (University of Kiel)

Academic Appointments

• 2024- : Visiting Professor for Mycobacterial Diseases, UKE, Hamburg
• 2023- : Member of the Board of Directors, Secretary General, The UNION
• 2021- : Affiliated Professor, Baylor College of Medicine, Houston, TX, USA
• 2018- : Medical Director, Research Center Borstel, Borstel, Germany
• 2018-2021: Affiliated Professor, Umeå University, Umeå (Sweden)
• 2017-2021: Chief of Medicine, Research Center Borstel, Borstel, Germany
• 2014-2020: Foreign Adjunct Professor, Karolinska Institutet, Stockholm (Sweden)
• 2014- : Professor (W3) Respiratory Medicine/Int. Health, University Lübeck
• 2012- : Adjunct Professor of Medicine, USMF, Chisinau, Republic of Moldova

Important Scientific Prizes/Functions

• 2025: DZIF Translational Research Award
• 2024: Fellow of the Royal College of Physicians, London
• 2023: Hinduja Hospital TB Oration, India
• 2018: Memento Research Award for Neglected Diseases, Germany
• 2017: Spinoza Chair in Medicine, University of Amsterdam, The Netherlands
• 2014: Science Award, Doner´s Association for Research in Germany
• 2013: Doctor honoris causa, USMF, Chisinau, R Moldova
• 2011-2014: Assembly Head (Respiratory Infections) European Respiratory Society
• 2006-2012: Chair: Tuberculosis Network European Trialsgroup (TBNET)
  
  
• h-factor: 97 (Google Scholar)
• Citations (life time) 37.153
• Number of publications: 469
• Public Grants (2019-2025): > 7.000.000 €
• Key words: tuberculosis, MDR-TB, NTMs, personalized medicine, clinical management

Current Projects

• 2021-2028: EU-IMI UNITE4TB, Clinical co-lead
• 2026-2030: DZIF ClinTB; Head

Selected publications 2024-2025:

2025

• Carratalà Castro L, et al. Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM). Clin Infect Dis. 2025 Nov 10:ciaf525. doi: 10.1093/cid/ciaf525.
• Chesov D, et al. High rates of acquired resistance to fluoroquinolones, bedaquiline and linezolid in patients failing treatment against drug-resistant tuberculosis in the Republic of Moldova. Clin Microbiol Infect. 2025 Sep 11: S1198-743X(25)00453-7. doi: 10.1016/j.cmi.2025.09.003.
• Garcia-Prats AJ, et al. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis. Lancet Child Adolesc Health. 2025 Feb;9(2):100-111. doi: 10.1016/S2352-4642(24)00330-4.
• Kherabi Y, et al. Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study. Lancet Reg Health Eur 2025, 56: 101380 September, DOI: 10.1016/j.lanepe.2025.101380
• Konstantynovska O, et al. Fluoroquinolone Resistance in Drug-Resistant Tuberculosis, Kharkiv, Ukraine, 2019-2023. Emerg Infect Dis. 2025 Mar;31(3):615-617. doi: 10.3201/eid3103.241675. PMID: 40023819;
• Lange B, et al. Tuberculosis incidence in solid organ transplant recipients in Europe: A multicenter TBnet cohort study. J Infect. 2025 Dec 20:106668. doi: 10.1016/j.jinf.2025.106668.
• Lange C, et al. Linezolid for the treatment of drug-resistant tuberculosis. Eur Respir J. 2025 Aug 22;66(2):2500927. doi: 10.1183/13993003.00927-2025
• Kasule GW, et al. Performance of stool Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis among adults living with HIV: a multicentre, prospective diagnostic study. Lancet Microbe. 2025 Mar 28:101085. doi: 10.1016/j.lanmic.2025.101085.
• Kunst H, et al. Tuberculosis in adult migrants in Europe: a TBnet consensus statement. Eur Respir J. 2025 Jan 30:2401612. doi: 10.1183/13993003.01612-2024.
• Moreira-Sousa D, et al. Consensus on Management of Refractory Nontuberculous Mycobacterial Pulmonary Disease. Eur Respir J. 2025 Nov 6:2500400. doi: 10.1183/13993003.00400-2025.
• Neumann M, et al. The molecular bacterial load assay predicts treatment responses in patients with pre-XDR/XDR-tuberculosis more accurately than GeneXpert Ultra MTB/Rif. J Infect. 2025 Feb;90(2):106399. doi: 10.1016/j.jinf.2024.106399.
• Peterka M, et al. Safety of high dose bedaquiline treatment in extensively drug-resistant (XDR)-TB patients. Eur Respir J. 2025 Nov 6:2501496. doi: 10.1183/13993003.01496-2025. Epub ahead of print. PMID: 41198387.
• Pichlo S, et al. Lipoarabinomannan (LAM) for the diagnosis of tuberculosis from sputum. J Infect. 2025 Nov 18;91(6):106662. doi: 10.1016/j.jinf.2025.106662. Online ahead of print. PMID: 41265528
• Rauch A, et al. Long-Term Self-Administered Outpatient Parenteral Antimicrobial Therapy in the Treatment of Tuberculosis. Drugs. 2025 Jan;85(1):87-96. doi: 10.1007/s40265-024-02122-4.
• Sester M, et al. Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study. Lancet Reg Health Eur. 2025 Aug 6;57:101416. doi: 10.1016/j.lanepe.2025.101416. PMID: 40823191
• Vasiliu A, et al. Shifting tuberculosis dynamics in the EU/EEA: geographical and drug resistance trends among people of foreign origin, 2019 to 2023. Euro Surveill. 2025 Mar;30(11). doi: 10.2807/1560-7917.ES.2025.30.11.2500173. PMID: 40116035.
• Woelk D, et al. Non-invasive diagnosis of pulmonary tuberculosis using face mask sampling: A prospective study in adults. Clin Microbiol Infect. 2025 Dec 29:S1198-743X(25)00628-7. doi: 10.1016/j.cmi.2025.12.017.
• Youngquist BM, et al. Rapid tuberculosis diagnosis from respiratory or blood samples by a low cost, portable lab-in-tube assay. Sci Transl Med. 2025 Apr 9;17(793):eadp6411. doi: 10.1126/scitranslmed.adp6411.

2024

• Brehm TT, et al. (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review. Clin Microbiol Infect. 2024 Apr 23: S1198-743X(24)00206-4. doi: 10.1016/j.cmi.2024.04.011.
• Carratalà Castro L, et al. Use of stool-based molecular tests for pediatric tuberculosis diagnosis: a systematic review and meta-analysis.  Lancet Microbe. 2024 Nov 9:100963. doi: 10.1016/j.lanmic.2024.100963.
• Cirillo DM et al. Handing over the baton: A successful UN High-Level Meeting on AMR must build on the 2023 UN High-Level Meeting on TB. Lancet Glob Health. 2024 Aug;12(8):e1225-e1226. doi: 10.1016/S2214-109X(24)00229-8.
• Dheda K, et al. Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024 Mar 24;10(1):22. doi: 10.1038/s41572-024-00504-2.
• Dheda K, et al. Towards shorter, safer, flexible, and more effective treatment regimens for drug-resistant tuberculosis. Lancet Respir Med. 2024 Oct 1:S2213-2600(24)00300-X. doi: 10.1016/S2213-2600(24)00300-X.
• Diacon AH, et al. Fourteen-day treatment responses in participants with rifampicin-susceptible pulmonary tuberculosis receiving the leucyl-tRNA synthetase inhibitor GSK3036656: a phase 2a open-label, randomized trial. Nat Med 2024 https://doi.org/10.1038/s41591-024-02829-7
• Gillespie SH, et al. Developing biomarkers assays to accelerate tuberculosis drug development: defining target product profiles. Lancet Microbe 2024, Published Online, https://doi.org/10.1016/S2666-5247(24)00085-5
• Günther G, et al.  Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe. Clin Microbiol Infect. 2024 Mar 13:S1198-743X(24)00121-6. doi: 10.1016/j.cmi.2024.03.009
• Hoelscher M, et al. Candidate anti-tuberculosis medicines and regimens under clinical evaluation. Clin Microbiol Infect. 2024 Jun 21:S1198-743X(24)00296-9. doi: 10.1016/j.cmi.2024.06.016.
• Kay A, et al. Performance of a quantitative stool polymerase chain reaction assay for the diagnosis of tuberculosis: a multinational diagnostic accuracy study. Lancet Microbe 2024 Mar 7: S2666-5247(23)00391-9. doi: 10.1016/S2666-5247(23)00391-9.
• Lienhardt C, et al. Target regimen profiles: shaping the future of tuberculosis treatment. Bull World Health Organ. 2024 Aug 1;102(8):600-607. doi: 10.2471/BLT.24.291881.
• Martinez L, et al. Effectiveness of preventive treatment among persons with differing age and Mycobacterium tuberculosis infection status: A systematic review and individual-participant meta-analysis of contact tracing studies Lancet Respir Med 2024 Published Online, https://doi.org/10.1016/S2213-2600(24)00083-3
• Nyang'wa BT, et al.  Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 2024 Feb;12(2):117-128. doi: 10.1016/S2213-2600(23)00389-2
• Shaw ES, et al. Bedaquiline: what might the future hold? Lancet Microbe. 2024 Jul 26:100909. doi: 10.1016/S2666-5247(24)00149-6
• Stoycheva K, et al. Tuberculosis in people of Ukrainian origin in the European Union and the European Economic Area, 2019 to 2022. Stoycheva K, Cristea V, Ködmön C, Rosales-Klintz S, Zenner D, Vasiliu A, van der Werf M, Lange C. Euro Surveill. 2024 Mar;29(12). doi: 10.2807/1560-7917.ES.2024.29.12.2400094.
• Wetzstein N, et al. Clinical spectrum and relevance of Mycobacterium malmoense: systematic review and meta-analysis of 859 patients. J Infect. 2024 Jun 19:106203. doi: 10.1016/j.jinf.2024.106203.